State Street Corp Boosts Position in Agenus Inc. (NASDAQ:AGEN)

State Street Corp boosted its position in Agenus Inc. (NASDAQ:AGEN) by 2.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 467,771 shares of the biotechnology company’s stock after purchasing an additional 9,731 shares during the period. State Street Corp owned about 1.99% of Agenus worth $2,563,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Point72 DIFC Ltd purchased a new position in shares of Agenus in the second quarter worth approximately $51,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Agenus in the second quarter worth approximately $106,000. HighTower Advisors LLC boosted its stake in shares of Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after acquiring an additional 7,530 shares during the last quarter. Exchange Traded Concepts LLC grew its position in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after acquiring an additional 9,422 shares during the period. Finally, BNP Paribas Financial Markets grew its position in shares of Agenus by 2,271.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 39,533 shares of the biotechnology company’s stock valued at $217,000 after acquiring an additional 37,866 shares during the period. 61.46% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Agenus in a report on Thursday, December 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.00.

Agenus Price Performance

AGEN opened at $2.74 on Wednesday. The company has a 50 day simple moving average of $3.41 and a two-hundred day simple moving average of $6.33. The firm has a market cap of $64.28 million, a P/E ratio of -0.24 and a beta of 1.24. Agenus Inc. has a 1-year low of $2.50 and a 1-year high of $19.69.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.